Eli Lilly and Company (NYSE:LLY) Shares Sold by Bath Savings Trust Co

Bath Savings Trust Co lessened its holdings in Eli Lilly and Company (NYSE:LLY) by 1.5% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 21,156 shares of the company’s stock after selling 325 shares during the period. Eli Lilly and Company makes up 1.8% of Bath Savings Trust Co’s investment portfolio, making the stock its 19th largest position. Bath Savings Trust Co’s holdings in Eli Lilly and Company were worth $17,473,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of the business. Quent Capital LLC increased its position in shares of Eli Lilly and Company by 2.5% during the 1st quarter. Quent Capital LLC now owns 5,575 shares of the company’s stock worth $4,604,000 after purchasing an additional 136 shares during the last quarter. Baring Financial LLC increased its position in shares of Eli Lilly and Company by 10.7% during the first quarter. Baring Financial LLC now owns 299 shares of the company’s stock valued at $247,000 after acquiring an additional 29 shares during the last quarter. Legacy Private Trust Co. increased its position in shares of Eli Lilly and Company by 6.7% during the first quarter. Legacy Private Trust Co. now owns 10,257 shares of the company’s stock valued at $8,471,000 after acquiring an additional 641 shares during the last quarter. Central Pacific Bank Trust Division increased its position in shares of Eli Lilly and Company by 15.9% during the first quarter. Central Pacific Bank Trust Division now owns 7,486 shares of the company’s stock valued at $6,183,000 after acquiring an additional 1,027 shares during the last quarter. Finally, Versant Capital Management Inc lifted its holdings in shares of Eli Lilly and Company by 68.0% in the 1st quarter. Versant Capital Management Inc now owns 1,961 shares of the company’s stock worth $1,620,000 after acquiring an additional 794 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Stock Up 0.2%

Shares of NYSE:LLY opened at $720.91 on Friday. The firm’s 50 day moving average price is $779.13 and its 200 day moving average price is $800.51. The stock has a market cap of $683.24 billion, a price-to-earnings ratio of 61.56, a price-to-earnings-growth ratio of 1.40 and a beta of 0.48. Eli Lilly and Company has a fifty-two week low of $677.09 and a fifty-two week high of $972.53. The company has a quick ratio of 0.97, a current ratio of 1.15 and a debt-to-equity ratio of 2.00.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Thursday, May 1st. The company reported $3.34 EPS for the quarter, missing the consensus estimate of $4.64 by ($1.30). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. The firm had revenue of $12.73 billion for the quarter, compared to analyst estimates of $12.77 billion. During the same quarter last year, the firm earned $2.58 EPS. The company’s revenue was up 45.2% on a year-over-year basis. As a group, equities research analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 10th. Stockholders of record on Friday, May 16th will be given a dividend of $1.50 per share. The ex-dividend date of this dividend is Friday, May 16th. This represents a $6.00 annualized dividend and a dividend yield of 0.83%. Eli Lilly and Company’s dividend payout ratio is currently 48.82%.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on LLY. The Goldman Sachs Group upgraded shares of Eli Lilly and Company from a “neutral” rating to a “buy” rating and dropped their target price for the company from $892.00 to $888.00 in a report on Tuesday, April 8th. Cantor Fitzgerald started coverage on Eli Lilly and Company in a research note on Tuesday, April 22nd. They issued an “overweight” rating and a $975.00 price objective for the company. Hsbc Global Res cut Eli Lilly and Company from a “strong-buy” rating to a “moderate sell” rating in a research note on Monday, April 28th. HSBC lowered Eli Lilly and Company from a “buy” rating to a “reduce” rating and decreased their target price for the stock from $1,150.00 to $700.00 in a research note on Monday, April 28th. Finally, Wall Street Zen raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Friday, February 7th. One analyst has rated the stock with a sell rating, two have given a hold rating and eighteen have given a buy rating to the company. According to data from MarketBeat.com, Eli Lilly and Company has a consensus rating of “Moderate Buy” and an average target price of $1,011.37.

Insider Transactions at Eli Lilly and Company

In other news, CAO Donald A. Zakrowski sold 1,000 shares of the firm’s stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $818.24, for a total transaction of $818,240.00. Following the sale, the chief accounting officer now owns 5,840 shares of the company’s stock, valued at approximately $4,778,521.60. This trade represents a 14.62% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.13% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.